Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.31 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL390748 | 0.91 | ALDH1A1 (0.44) | KMT2AMEN1ALDH1A1KDM4EGLA | |
| SCHEMBL390783 | 0.91 | ALDH1A1 (0.41) | KMT2AMEN1ALDH1A1KDM4EGLA | |
| SCHEMBL1544893 | 0.90 | ALDH1A1 (0.46) | KMT2AMEN1ALDH1A1KDM4EGLA | |
| SCHEMBL17725440 | 0.86 | MEN1 (0.58) | KMT2AMEN1ALDH1A1KDM4EGLA | |
| SCHEMBL4872348 | 0.86 | PDE1B (0.38) | KMT2AMEN1ALDH1A1 | |
| SCHEMBL18454281 | 0.85 | MEN1 (0.35) | KMT2AMEN1ALDH1A1KDM4EGLA | |
| SCHEMBL18453784 | 0.79 | MEN1 (0.30) | KMT2AMEN1 | |
| SCHEMBL19612578 | 0.79 | DRD2 (0.35) | KMT2AMEN1 | |
| SCHEMBL19629573 | 0.78 | DRD2 (0.30) | — | |
| SCHEMBL17725191 | 0.75 | DRD2 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3210469-A1 | USE OF SUBSTITUTED THIO-1,2,4-TRIAZOLES FOR INCREASING STRESS TOLERANCE IN PLANTS | Bayer Cropscience AG (DE) | 2017-08-30 | — | — | EP | disclosed |
| EP-1817037-B1 | TRIAZOLE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | ABBOTT GMBH & CO KG (DE) | 2013-04-03 | — | — | EP | disclosed |
| US-8202868-B2 | 4-piperazinyl-pyrimidine compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor | ABBOTT GMBH & CO. KG (DE) | 2012-06-19 | — | — | US | disclosed |
| US-20120095015-A1 | TRIAZOLE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2012-04-19 | — | — | US | disclosed |
| US-8101754-B2 | e.g., 2-tert-Butyl-4-{4-[3-(4-methyl-5-methyl-4H-[1,2,4]triazol-3-ylsulfanyl)-propyl]-piperazin-1-yl}-6-(1-methylcyclopropyl)-pyrimidine hydrochloride; central nervous system disorders; schizophrenia; antidepressant, anxiolytic agent, cognition activator; Parkinson's and Alzheimer's diseases | ABBOTT GMBH & CO. KG (DE) | 2012-01-24 | — | — | US | disclosed |
| EP-1891056-B1 | NOVEL COMPOUNDS | GLAXO GROUP LTD (GB) | 2010-10-13 | — | — | EP | disclosed |
| US-7807698-B2 | Azabicyclo[3.1.0]hexane derivatives as modulators of the dopamine D3 receptor | GLAXO GROUP LIMITED (GB) | 2010-10-05 | — | — | US | disclosed |
| US-7807698-B2 | Azabicyclo[3.1.0]hexane derivatives as modulators of the dopamine D3 receptor | GLAXO GROUP LIMITED (GB) | 2010-10-05 | — | — | US | disclosed |
| EP-1778684-B1 | 4-PIPERAZINYL-PYRIMIDINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D<sb>3</sb> RECEPTOR | ABBOTT GMBH & CO KG (DE) | 2009-12-16 | — | — | EP | disclosed |
| US-20090264437-A1 | 4-Piperazinyl-Pyrimidine Compounds Suitable for Treating Disorders that Respond to Modulation of the Dopamine D3 Receptor | ABBOTT GMBH & CO. KG (DE) | 2009-10-22 | — | — | US | disclosed |
| CN-101384263-A | Is suitable for treating dopamine D3Triazole compounds for receptor-mediated diseases | ABBOTT GMBH & CO KG (DE) | 2009-03-11 | — | — | CN | disclosed |
| US-20080227837-A1 | Novel Compounds | GLAXO GROUP LIMITED (GB) | 2008-09-18 | — | — | US | disclosed |
| US-20080227837-A1 | Novel Compounds | GLAXO GROUP LIMITED (GB) | 2008-09-18 | — | — | US | disclosed |
| US-20080171751-A1 | Triazole Compounds Suitable for Treating Disorders that Respond to Modulation of the Dopamine D3 Receptor | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2008-07-17 | — | — | US | disclosed |
| EP-1817037-A1 | TRIAZOLE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULAIONT OF THE DOPAMINE D3 RECEPTOR | Abbott GmbH & Co. KG (DE) | 2007-08-15 | — | — | EP | disclosed |
| EP-1778684-A1 | 4-PIPERAZINYL-PYRIMIDINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D&lt;sb&gt;3&lt;/sb&gt; RECEPTOR | Abbott GmbH & Co. KG (DE) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006058753-A1 | TRIAZOLE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULAIONT OF THE DOPAMINE D3 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2006-06-08 | — | — | WO | disclosed |
| WO-2006015842-A1 | 4-PIPERAZINYL-PYRIMIDINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2006-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264437-A1 | 4-Piperazinyl-Pyrimidine Compounds Suitable for Treating Disorders that Respond to Modulation of the Dopamine D3 Receptor | ADRA1D, ADRA1A, ADRA2A | KMT2A 1795/4885MEN1 4664/4885ALDH1A1 250/4885 |
| US-20120095015-A1 | TRIAZOLE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | ADRB3, DRD3, ADORA3 | KMT2A 3677/4885MEN1 2438/4885ALDH1A1 511/4885 |
| US-20080171751-A1 | Triazole Compounds Suitable for Treating Disorders that Respond to Modulation of the Dopamine D3 Receptor | ADRB3, DRD3, ADORA3 | KMT2A 3803/4885MEN1 2389/4885ALDH1A1 606/4885 |
| US-20080227837-A1 | Novel Compounds | HTR5A, NPY5R, DRD3 | KMT2A 4458/4885MEN1 4379/4885ALDH1A1 1382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.